Physician profile
Deepika Gopalakrishnan
NPI 1487646048
$1,927.06
in general payments reported to CMS, 2019-2025
29 companies · $63.58 in 2025
The $63.58 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $92.93 · 2021: $301 · 2022: $449 · 2023: $394 · 2024: $209 · 2025: $63.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $279.56 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $256.82 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $198.66 | 2022-2024 | Verquvo |
| Amgen INC. | $163.98 | 2019-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $152.58 | 2019-2023 | Lifevest |
| Novo Nordisk INC | $73.77 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Kiniksa Pharmaceuticals International, Plc | $70.31 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $65.56 | 2019-2023 | Andexxa |
| Regeneron Healthcare Solutions, INC. | $63.57 | 2019 | |
| Astellas Pharma US INC | $54.34 | 2019-2021 | |
| Abbott Laboratories | $48.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.33 | 2022-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.79 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $45.21 | 2022-2023 | Arcalyst |
| Philips North America LLC | $42.62 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $38.23 | 2025 | |
| Sanofi-Aventis U.S. LLC | $30.09 | 2019 | |
| Daiichi Sankyo INC. | $29.77 | 2023 | Injectafer |
| Pfizer INC. | $28.59 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.73 | 2019-2022 | |
| Itamar Medical INC | $23.64 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.69 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $21.04 | 2021 | |
| Chiesi USA, INC. | $20.45 | 2023 | Cleviprex, Kengreal |
| Scpharmaceuticals INC. | $18.09 | 2023 | |
| Tactile Systems Technology INC | $17.60 | 2022 | |
| Bardy Diagnostics, INC. | $15.39 | 2019-2020 | |
| Ge Healthcare | $13.18 | 2019 | |
| Boston Scientific Corporation | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Gopalakrishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.